Medicare Prescription Drug Benefit Has 'Largely Succeeded' In Providing Coverage For Many Beneficiaries, But Must Address Shortcomings, Editorial
Main Category: Medicare / Medicaid / SCHIPArticle Date: 06 Sep 2007 - 8:00 PDT
The Medicare prescription drug benefit "has largely succeeded in its primary goal of providing drug coverage to Medicare beneficiaries who previously lacked it," but "it has fallen short in providing subsidies to low-income Americans, in protecting people from high out-of-pocket costs and in matching the benefits offered by other private and public sources of coverage," a New York Times editorial states. "Hefty subsidies" for low-income Medicare beneficiaries enrolled in prescription drug plans "have made a big difference in cutting costs for those who received them," the editorial states. However, the editorial states that about "3.4 million to 4.7 million people who are eligible are not receiving the extra help, many because they are unaware of the benefit."
According to the editorial, a survey conducted last year by the Kaiser Family Foundation, Commonwealth Fund and Tufts-New England Medical Center found that although the Medicare prescription drug benefit "had a big impact in helping to reduce the percentage of older Americans without drug coverage," many beneficiaries "were less protected against high drug costs than their counterparts in other plans."
The editorial adds, "The unfortunate consequence for patient health is that Medicare enrollees were much more likely to postpone medications because of the cost." The editorial states, "These shortcomings will need attention as the program rolls forward," and "any tendency to consider the job done is to be avoided" (New York Times, 9/3).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our medicare / medicaid / schip section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/81536.php>
APA
http://www.medicalnewstoday.com/releases/81536.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Medicare Prescription Drug Benefit Has Succeeded In Providing Coverage
posted by Gregory D. Pawelski on 6 Sep 2007 at 9:55 pmA National Coalition for Cancer Survivorship poll found that 89% of Americans said that the distinction between oral and intravenous applications should be abolished so that Medicare beneficiaries can have access to the best drugs to treat their form of cancer.
Apparently Medicare has gone far in accomplishing the task of making many cancer drugs available to our Seniors. Nearly all generic cancer drugs and 70% of brand-name cancer drugs are covered by the Part D plans. Most of the brand-name drugs not covered had generic equivalents that are covered. And a number of trusted old generic agents have been found to be just as effacious as the more expensive brand name ones.
The study, published in the journal Health Affairs, discovered that Part D expanded access to cancer therapies and required only low co-payments. Researchers found that the most commonly prescribed cancer drugs were available and when a brand-name drug was not covered, its generic equivalent was.
More chemotherapy is given for breast cancer than for any other form of cancer and there have been more published reports of clinical trials for breast cancer than for any other form of cancer. So, according to NCI's official cancer information website on "state of the art" chemotherapy for recurrent or metastatic breast cancer, it is unclear whether single-agent chemotherapy or combination chemotherapy is preferable for first-line treatment.
At this time, no data support the superiority of any particular regimen. So, it would appear that published reports of clinical trials provide precious little in the way of guidance. There are many cancer drug regimens, all of which have approximately the same probability of working. The tumors of different patients have different responses to chemotherapy. It requires individualized treatment based on testing the individual properties of each patient's cancer.
Oral chemotherapeutic agents are easy to use and offer the promise of less frequent visits to oncology-based offices and their infusion rooms. This promise is not trivial, especially as we have come to realize that many forms of cancer may be managed with these drugs, especially when they offer the equivalent outcome as intravenous drugs.
Now, only if Medicare would be allowed price negotiations, eliminate the doughnut hole, and stop subsidizing private insurance Medicare plans!
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





